Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer
Authors
Keywords
STMN1, Sensitivity, Prognosis, NSCLC, TAX, Chemotherapy
Journal
TUMOR BIOLOGY
Volume 36, Issue 9, Pages 7195-7204
Publisher
Springer Nature
Online
2015-04-17
DOI
10.1007/s13277-015-3361-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Quest for a Simple Bioactive Analog of Paclitaxel as a Potential Anticancer Agent
- (2014) David G. I. Kingston et al. ACCOUNTS OF CHEMICAL RESEARCH
- Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer
- (2014) Christina D. Williams et al. CANCER
- Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
- (2014) Christian Rolfo et al. CANCER TREATMENT REVIEWS
- The tubulin code: Molecular components, readout mechanisms, and functions
- (2014) Carsten Janke JOURNAL OF CELL BIOLOGY
- Usefulness of the Palliative Prognostic Index in patients with lung cancer
- (2014) Minehiko Inomata et al. MEDICAL ONCOLOGY
- Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
- (2014) Henrica M. J. Werner et al. PLoS One
- STMN-1 Gene: A Predictor of Survival in Stage IIA Esophageal Squamous Cell Carcinoma After Ivor-Lewis Esophagectomy?
- (2013) Javed Akhtar et al. ANNALS OF SURGICAL ONCOLOGY
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- Overcoming Paclitaxel Resistance in Lung Cancer Cells Via Dual Inhibition of Stathmin and Bcl-2
- (2013) Zheng-Xiang Han et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients
- (2013) Jan Nyrop Jakobsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition
- (2013) J. M. Buonato et al. CANCER RESEARCH
- Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
- (2013) S.A. Laurie et al. EUROPEAN JOURNAL OF CANCER
- Results of platinum-based chemotherapy in unselected performance status (PS) 2 patients with advanced non-small cell lung cancer: a cohort study
- (2013) Stéphane Jouveshomme et al. MEDICAL ONCOLOGY
- A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer
- (2013) Giuseppe Luigi Banna et al. MEDICAL ONCOLOGY
- Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of III-Tubulin Expression as a Predictive Marker
- (2013) C. Saura et al. ONCOLOGIST
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer
- (2012) Lei Liu et al. Cancer Epidemiology
- Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non–Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor Mutation
- (2012) Chun-Ming Tsai et al. Journal of Thoracic Oncology
- Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis
- (2012) Hai-Long Zhang et al. LUNG CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Class III -Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial
- (2011) A. C. Vilmar et al. CLINICAL CANCER RESEARCH
- In vivo Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein
- (2011) Anagha P. Phadke et al. DNA AND CELL BIOLOGY
- Stathmin: a protein with many tasks. New biomarker and potential target in cancer
- (2011) Barbara Belletti et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
- (2009) Dan Su et al. CANCER
- Stathmin 1: a novel therapeutic target for anticancer activity
- (2008) Shushan Rana et al. Expert Review of Anticancer Therapy
- Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients
- (2008) Wang Xi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started